Status:
COMPLETED
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Lead Sponsor:
Facet Biotech
Conditions:
Ulcerative Colitis
Gastrointestinal Disease
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research c...
Eligibility Criteria
Inclusion
- Moderate to severe active ulcerative colitis diagnosed for at least 4 months.
- Mayo score of 5-10 (inclusive)
- Not used any investigational therapy for 30 days prior to screening
- No treatment with monoclonal antibody therapy within 12 weeks of screening
- No prior treatment with daclizumab
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00073047
Start Date
April 1 2003
End Date
July 1 2006
Last Update
July 20 2009
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Associates
Huntsville, Alabama, United States, 35801
2
Advanced Medical Research Institute
Anaheim, California, United States, 92801
3
Research Foundation of America
Los Angeles, California, United States, 90035
4
Western Gastroenterology Group
Los Angeles, California, United States, 90045